Low-grade gliomas and secondary glioblastomas are characterized by mutations in IDH1/2 (isocitrate dehydrogenase 1/2), which are associated with a longer overall survival and better response to therapy compared to IDH-wildtype gliomas [1,2,3,4]. The gene discussed is IDH1; the disease is glioma.